The news follows the company’s opening US offices in Delaware during 2019
Bora Pharmaceuticals has successfully completed the acquisition of GSK’s Mississauga, Ontario (Canada) facility.
Initially announced in March 2020, the site will be Bora Pharmaceuticals’ first manufacturing facility in North America and will become its headquarters in the region.
“Completing the acquisition marks a major step in our expansion into North America, bringing us closer to many of our current and future customers.” said Bobby Sheng, CEO of Bora Pharmaceuticals. “The Mississauga site strengthens our existing state-of-the-art manufacturing network, broadening our capabilities and almost doubling our number of talented colleagues, so that we can continue to support the current and future needs of our customers.”
Through this acquisition, Bora Pharmaceuticals will broaden its range of dosage forms. The addition of the site enables it to produce 50 different products for 100 markets. The transaction includes a minimum five-year supply agreement with GSK.
The company hopes its international reputation will help strengthen Canada’s medicines supply chain.
“Our government is proud that Bora chose Ontario for this significant investment. We have a world-class life sciences sector, and this new investment by Bora will strengthen it even further,” said Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. “Our workforce is the best in the world, and certainly up to the challenge of helping Bora grow and thrive here in Ontario.”
“By choosing Mississauga for its flagship North American facility, Bora Pharmaceuticals has reinforced what so many other notable companies already know – that the life sciences sector is thriving in our City and it’s the perfect location to call home,” said Mayor Bonnie Crombie. “As the second largest life sciences sector in Canada, the talent pool of scientists, experts and engineers in Mississauga is driving technologies and innovations used worldwide. I’m thrilled to welcome Bora Pharmaceuticals to this illustrious group.”
Whilst the company will retain the vast majority of the workforce at the site, it will hire additional employees to the technical and operational team in line with its growth plans.